UBS’s Arcturus Therapeutics ARCT Stock Holding History

UBS’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	$261K	Buy	+2,414	New	+$315K	﹤0.01%	4915

Other funds holding ARCT

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AWMDMG

Austin W. Marxe & David M. Greenhouse New York $733M AUM 21.72% 1-Year Est. Return

GLG LLC New York $1.39B AUM 24.01% 1-Year Est. Return

Sophrosyne Capital New York $11.5M AUM 17.82% 1-Year Est. Return

EAM

EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

UBS's ARCT Position: Q3 2014 in Review

UBS increased its Arcturus Therapeutics (ARCT) stake by 713% in Q3 2014, buying an estimated $344K and bringing the position to 3,009 shares worth $325K. The position accounts for ﹤0.01% of the portfolio, ranked #4694.

UBS first reported a position in ARCT in Q2 2013 and has held it in 4 quarters since. 38 funds tracked by Wall St. Rank hold ARCT as of Q3 2014.

UBS held 3,009 shares of Arcturus Therapeutics worth $325K as of Q3 2014.
UBS bought 2,639 Arcturus Therapeutics shares in Q3 2014, an estimated $344K.
Arcturus Therapeutics made up ﹤0.01% of UBS's portfolio in Q3 2014, its #4694 holding.
UBS first reported a position in Arcturus Therapeutics in Q2 2013 and has held it in 4 quarters since.
38 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.